CVE-2026-126681: AWS Labs Timestream · Improper Restriction of Intended Endpoints
Source AWS Security Bulletins
Not known to be exploited · CVSS 5.5 Medium : upgrade to 0.0.19 when convenient.
Data as of 16 Nov 2026, 21:19 UTC
Thin evidence
One scorer or none| CNA (AMZN) | CVSS 3.1 | 5.5 |
|---|---|---|
| CNA (AMZN) | CVSS 4.0 | 6.8 |
- Patch
- Available – fixed in 0.0.19
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:N/A:NExploitation evidence
Disclosed: evidence found.
CVE published 16 Nov 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponized: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 16 Nov 2026.
What to do
Upgrade timestream-for-influxdb-mcp-server to 0.0.19.
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| AWStimestream-for-influxdb-mcp-server | Affected
| Fixed in
|
Check your own hosts for these packages with threat-finder (opens in a new tab), our free open-source scanner.
AI-suggested
Upgrade to version 0.0.19 or later of AWS Labs Timestream for InfluxDB MCP Server, where this vulnerability is fixed. Since the affected versions are explicitly stated as >=0.0.12 and <0.0.19, applying this update will remediate the issue. No other mitigation or temporary workaround is provided in the available data.
Description
CVE-2026-126681 is a vulnerability in AWS Labs Timestream for InfluxDB MCP Server versions 0.0.12 up to but not including 0.0.19. It involves improper restriction of intended endpoints in connection configuration handling, which may allow a remote unauthenticated attacker to obtain the InfluxDB API token by exploiting prompt injection through a crafted InfluxDB URL.